{"id":"da-2811-c","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL578465","moleculeType":"Small molecule","molecularWeight":"587.71"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Limited public information is available on the precise molecular mechanism of DA-2811-C. As a Phase 2 investigational drug from Dong-A ST Co., Ltd., detailed mechanistic data may not yet be fully disclosed in the public domain.","oneSentence":"DA-2811-C is a small molecule inhibitor targeting a specific cellular pathway involved in disease pathogenesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:30:47.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07239440","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"NOT_YET_RECRUITING","sponsor":"Dong-A ST Co., Ltd.","startDate":"2025-11","conditions":"Diabete Mellitus","enrollment":288}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DA-2811-C","genericName":"DA-2811-C","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}